Maze Therapeutics, Inc. · NASDAQ:MAZE
ARCH Venture Fund X, L.P. reported a 9.40% stake in Maze Therapeutics, Inc. (Schedule 13G)
Event Mar 31, 2025 · Filed May 15, 2025
ARCH Venture Fund X, L.P. reported a 9.40% stake in Maze Therapeutics, Inc., 4,120,053 shares, as a passive investor on Mar 31, 2025. Filed May 15, 2025 (Schedule 13G).
- Stake
- 9.40%
- Shares
- 4,120,053
- Intent
- Passive
- What changed
- Crossed above 5%
- Filed together
- 9 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| ARCH Venture Fund X, L.P. | 9.40% | 4,120,053 |
| ARCH Venture Fund X Overage, L.P. | 9.40% | 4,120,053 |
| ARCH Venture Partners X, L.P. | 9.40% | 4,120,053 |
| ARCH Venture Partners X Overage, L.P. | 9.40% | 4,120,053 |
| ARCH Venture Partners X, LLC | 9.40% | 4,120,053 |
| Keith Crandell | 9.40% | 4,120,053 |
| Kristina Burow | 9.40% | 4,120,053 |
| Steven Gillis | 9.40% | 4,120,053 |
| Robert Nelsen | 9.40% | 4,120,053 |